MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has initiated the third phase 3 study of Qnexa in obese patients with co-morbidities. The EQUATE study (OB-301) will enroll 700 patients with Body Mass Index (“BMI”) ranging from 30 to 45. The co-primary endpoints for these studies will evaluate the differences between treatments in mean percent weight loss and in the percentage of subjects achieving weight loss of 5% or more. Patients will be studied over 28 weeks.
